Gonzalez M
Int J Mol Sci. 2017; 18(1).
PMID: 28075409
PMC: 5297760.
DOI: 10.3390/ijms18010126.
Kubo Y, Izumida M, Yashima Y, Yoshii-Kamiyama H, Tanaka Y, Yasui K
Oncotarget. 2016; 7(44):71255-71273.
PMID: 27655726
PMC: 5342076.
DOI: 10.18632/oncotarget.12104.
Zhou X, DeLucia M, Ahn J
J Biol Chem. 2016; 291(33):16936-16947.
PMID: 27354282
PMC: 5016100.
DOI: 10.1074/jbc.M116.721183.
Kubler J, Kirschner S, Hartmann L, Welzel G, Engelhardt M, Herskind C
Oncotarget. 2016; 7(29):45500-45512.
PMID: 27275537
PMC: 5216737.
DOI: 10.18632/oncotarget.9787.
Trinite B, Chan C, Lee C, Levy D
J Virol. 2015; 90(2):904-16.
PMID: 26537673
PMC: 4702666.
DOI: 10.1128/JVI.01770-15.
SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Casini N, Forte I, Mastrogiovanni G, Pentimalli F, Angelucci A, Festuccia C
Oncotarget. 2015; 6(14):12421-35.
PMID: 25762618
PMC: 4494948.
DOI: 10.18632/oncotarget.3043.
Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells.
Trinite B, Chan C, Lee C, Mahajan S, Luo Y, Muesing M
PLoS One. 2014; 9(10):e110719.
PMID: 25330112
PMC: 4199762.
DOI: 10.1371/journal.pone.0110719.
The effect of cellular differentiation on HSV-1 infection of oligodendrocytic cells.
Bello-Morales R, Crespillo A, Garcia B, Dorado L, Martin B, Tabares E
PLoS One. 2014; 9(2):e89141.
PMID: 24551233
PMC: 3923881.
DOI: 10.1371/journal.pone.0089141.
An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.
Trinite B, Ohlson E, Voznesensky I, Rana S, Chan C, Mahajan S
J Virol. 2013; 87(23):12701-20.
PMID: 24049167
PMC: 3838139.
DOI: 10.1128/JVI.01939-13.
Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy.
Shults K, Flye-Blakemore L, Patterson B, Elbeik T
Future Virol. 2012; 7(8):819-832.
PMID: 23125871
PMC: 3486786.
DOI: 10.2217/fvl.12.69.
The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains.
Solbak S, Wray V, Horvli O, Raae A, Flydal M, Henklein P
BMC Struct Biol. 2011; 11:49.
PMID: 22185200
PMC: 3269379.
DOI: 10.1186/1472-6807-11-49.
Human immunodeficiency virus viral protein R as an extracellular protein in neuropathogenesis.
Ferrucci A, Nonnemacher M, Wigdahl B
Adv Virus Res. 2011; 81:165-99.
PMID: 22094081
PMC: 3731056.
DOI: 10.1016/B978-0-12-385885-6.00010-9.
The intriguing cyclophilin A-HIV-1 Vpr interaction: prolyl cis/trans isomerisation catalysis and specific binding.
Solbak S, Reksten T, Wray V, Bruns K, Horvli O, Raae A
BMC Struct Biol. 2010; 10:31.
PMID: 20920334
PMC: 2959089.
DOI: 10.1186/1472-6807-10-31.
Cell cycle G2/M arrest through an S phase-dependent mechanism by HIV-1 viral protein R.
Li G, Park H, Liang D, Zhao R
Retrovirology. 2010; 7:59.
PMID: 20609246
PMC: 2909154.
DOI: 10.1186/1742-4690-7-59.
Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.
Irish B, Khan Z, Jain P, Nonnemacher M, Pirrone V, Rahman S
Am J Infect Dis. 2010; 5(3):231-258.
PMID: 20352020
PMC: 2845477.
DOI: 10.3844/ajidsp.2009.231.258.
Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
Ao Z, Yu Z, Wang L, Zheng Y, Yao X
PLoS One. 2008; 3(4):e1995.
PMID: 18414671
PMC: 2288674.
DOI: 10.1371/journal.pone.0001995.
Anti-Vpr activity of a yeast chaperone protein.
Benko Z, Liang D, Agbottah E, Hou J, Chiu K, Yu M
J Virol. 2004; 78(20):11016-29.
PMID: 15452222
PMC: 521794.
DOI: 10.1128/JVI.78.20.11016-11029.2004.
Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription.
Kutsch O, Levy D, Bates P, Decker J, Kosloff B, Shaw G
Antimicrob Agents Chemother. 2004; 48(5):1652-63.
PMID: 15105117
PMC: 400550.
DOI: 10.1128/AAC.48.5.1652-1663.2004.
Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious.
Gao F, Chen Y, Levy D, Conway J, Kepler T, Hui H
J Virol. 2004; 78(5):2426-33.
PMID: 14963138
PMC: 369203.
DOI: 10.1128/jvi.78.5.2426-2433.2004.
Using death to one's advantage: HIV modulation of apoptosis.
Ross T
Leukemia. 2001; 15(3):332-41.
PMID: 11237054
PMC: 1635155.
DOI: 10.1038/sj.leu.2402028.